r was acquired somewhat more frequently via primary transmission than by independent pathways. Our molecular analysis also revealed that several historic M. tuberculosis strains responsible for MDR TB outbreaks in the early 1990s were continuing to circulate in NYC. We conclude that the increasing incidence of PZA r , with clear microbial risk factors, underscores the importance of routine PZA drug susceptibility testing and M. tuberculosis genotyping for the identification, control, and prevention of increasingly resistant organisms.
P
yrazinamide (PZA) is a first-line antituberculosis (anti-TB) drug and the cornerstone of modern short-course chemotherapy. PZA acts synergistically with other TB drugs to accelerate culture conversion and reduce the risk of relapse among patients with drug-susceptible TB (1) . In patients with multidrug-resistant (MDR) TB, defined as resistance to at least isoniazid (INH) and rifampin (RIF), inclusion of PZA is recommended to reduce the treatment duration (2, 3) , while optimizing MDR TB treatment regimens based on PZA susceptibility may improve clinical outcomes (4) . Due to its well-documented sterilizing capability, PZA has been included in several new TB drug regimens (5) (6) (7) .
PZA is a prodrug that requires activation to pyrazinoic acid by the pyrazidamidase of M. tuberculosis under acidic conditions (8) . While at least one other M. tuberculosis gene has been associated with PZA resistance (PZA r ) (9) , mutations in pncA, which encodes the pyrazidamidase, account for the majority of PZA r in vitro (10, 11) . Most genes associated with drug resistance in M. tuberculosis, such as katG (INH) and rpoB (RIF), have clear mutational hot spot regions 7 to 66 nucleotides (nt) in length. In contrast, mutations observed in pncA span a region of ϳ600 nt, comprising the entire gene and the putative promoter region (10, 12, 13) . Growth-based assays of M. tuberculosis PZA susceptibility are the standard but are not always performed routinely, except in large referral laboratories, because they are technically challenging (14, 15) . However, pncA mutations in clinical M. tuberculosis isolates have generally been found to correlate with phenotypic PZA drug susceptibility testing (DST) results, supporting the value of pncA sequence analysis as an alternative means to establish PZA resistance (13, 16) .
Genetic markers have been used to confirm or refute TB outbreaks and to estimate the proportion of recent transmission in a population (17) . For instance, due to the wide diversity of pncA mutations, these sequences can provide a genetic marker to confirm or resolve genotypic clusters, where the presence of identical pncA mutations in genotypically clustered strains is supportive of primary transmission while genotypic clusters with diverse pncA mutations suggest acquired (de novo) PZA r , indicating these cases may not be epidemiologically related (17) .
Despite the unique role PZA plays in modern TB chemotherapy, few studies have investigated the epidemiology of PZA r in both general and MDR TB populations (18) . Using TB case records and surveillance data provided by the New York City (NYC) Department of Health and Mental Hygiene (DOHMH) from 2001 to 2008, we conducted a population-based study of M. tuberculosis isolates from 6,260 culture-positive TB cases to examine PZA r in terms of clinical, microbial, and demographic risk factors. Due to the clinical and epidemiologic importance of MDR TB, we also performed a case-control study to identify PZA r risk factors and examine PZA r acquisition and clustering among the MDR population.
MATERIALS AND METHODS
All incident culture-positive TB cases reported and verified by the NYC DOHMH between January 2001 and December 2008 (n ϭ 6,260) were included in the study (Fig. 1) . Routine genotyping was performed by the Public Health Research Institute (PHRI) Tuberculosis Center at Rutgers University (IS6110-restriction fragment length polymorphism [RFLP] ) and New York State Wadsworth Center (spoligotype) (19) . All strains with genotyping results available (n ϭ 5,877) were assigned a molecular lineage using the taxonomic designation previously described by Gagneux and Small (20) and a strain code following a nomenclature system of the PHRI TB Center that has been described previously (21, 22) . Strains identified as Mycobacterium bovis (n ϭ 68) or Mycobacterium africanum (n ϭ 78) (23) were omitted from our analysis. Clusters were defined as two or more strains sharing identical IS6110-RFLPs and spoligotypes. DST able for all cases with reduced susceptibility to any first-line agent. M. tuberculosis isolates were classified as MDR if they were resistant to at least INH and RIF (3). Isolates were classified as poly-PZA r if they were resistant to PZA and at least one other drug, excluding MDR isolates (Fig. 1) .
Data collection. Demographic and clinical information was provided by the NYC DOHMH TB Registry, which contains information for each reported TB patient obtained by interview and medical-record abstraction performed by trained Bureau of Tuberculosis Control (BTBC) staff, using standard data collection forms. Demographic variables included age at TB diagnosis, sex, birthplace (United States or foreign born with country of birth), number of years since arrival in the United States for foreignborn patients, and race/ethnicity. Sociodemographic variables included reported homelessness; substance use (injection drug use), noninjection crack cocaine use, or noninjection drug use (consolidated into yes or no); alcohol abuse; and history of TB treatment at Rikers Island Prison Complex. Clinical variables included initial chest radiography results (normal/ abnormal and absence/presence of cavities), the anatomical site of TB disease, respiratory acid-fast bacillus (AFB) smear status, final culture conversion (final conversion from positive to negative culture), HIV status (infected, uninfected, or unknown); and death from any cause (yes or no, excluding patients who refused treatment or were lost to follow-up).
All MDR isolates (n ϭ 159) were subjected to PCR amplification (primers, 5=-ATGCGGCGTTGATCATCG-3= and 5=-CAGGAGCTGCA AACCAACTCG-3=), followed by standard capillary sequencing of pncA promoter and coding DNA sequence (CDS), as previously described (12) . Mutations were identified by alignment of nucleotide sequences to the M. tuberculosis H37Rv reference strain (NCBI accession number AL123456) (25) using ClustalW2 (26) . All MDR isolates were also analyzed for the presence of known drug resistance-conferring mutations in the gene targets katG, fabG1 (promoter), and rpoB, using the IBIS platform (Ibis Biosciences Carlsbad, CA), which is based on PCR followed by electrospray ionization mass spectrometry, as described previously (27) .
Statistical analysis. All statistical analysis was performed using SAS (Cary, NC) 9.3. To examine aggregate patient risk factors associated with PZA r , unadjusted odds ratios (OR) were estimated using standard twoby-two contingency (17) . Finally, we evaluated the overall agreement between PZA susceptibility defined by phenotype (DST) and genotype (pncA sequence) among MDR isolates using a kappa statistic.
Ethical approval for this study was obtained from the Institutional Review Boards of the NYC DOHMH and Rutgers University (Newark, NJ). Table 3 shows the odds ratios for PZA r according to clinical and demographic characteristics, stratified by patients with MDR and non-MDR TB. Factors independently associated with PZA r among patients with MDR TB in the stratified analysis were EMB-SLD resistance and AFB smear positivity. AFB smear positivity was the only significant characteristic among patients with non-MDR TB (Table 3 ). In the multivariate MDR TB analysis, only EMB-SLD resistance (OR ϭ 3.48; 95% CI ϭ 1.57 to 7.69) maintained significance (Table 4) , while a history of latent M. tuberculosis infection (LTBI) trended toward significance (OR ϭ 0.12; 95% CI ϭ 0.01 to 1.07). Table 2 ). Among the non-MDR population, phylogenetic lineage 1 was the only PZA r predictor that maintained significance in the multivariate model (OR ϭ 3.27; 95% CI ϭ 1.64 to 6.51) ( Table 4) .
MDR TB case-control study. To examine PZA r risk factors among the 159 MDR cases, we performed a case-control study.
Sixty percent of MDR isolates (96/159) were considered genotypically clustered (identical IS6110-RFLPs and spoligotypes), with clusters ranging in size from 2 to 21 members. In contrast, only 43.6% (2,401/5,511) of the non-MDR strains were genotypically clustered (Table 3) . Forty-four percent of MDR isolates (70/159) were PZA r based on DST, 64% (45/70) of which belonged to a genotypic cluster. The genetic markers pncA, katG, and rpoB were used to further resolve clustering within the MDR population. Sequence data for the fabG1 promoter did not provide additional cluster resolution and are not shown.
Complete sequence data (katG, rpoB, and pncA) were available for 88% (140/159) of MDR M. tuberculosis isolates (Fig. 1) , while pncA sequence data were available for 143 isolates. Analysis of the pncA CDS-promoter region of MDR isolates identified 83 (58%) mutants. In total, there were 37 unique pncA mutations, which included insertions, deletions, and nonsynonymous substitutions. Some discordances between PZA r determined by DST and the presence of pncA mutations (PZA r -pncA) were observed (109/ 143; kappa ϭ 0.54). However, the majority of these were accounted for by a single family of Beijing strains (termed W; n ϭ 54) (29/54; kappa ϭ 0.17), many of which carried a specific pncA mutation known to exhibit discordance with phenotypic PZA r (16, 28) , as discussed below. Concordance between the pncA sequence and PZA DST results was significantly higher when W strains were excluded and the remaining 89 strains were evaluated (80/89; kappa ϭ 0.79). Table 5 shows the resolution of genotypic clusters, using DNA sequence data to distinguish primary transmission from independent acquisition of MDR TB. Identical sequences for katG, rpoB, and pncA confirmed the genotyping assignment of seven clusters (n ϭ 38). Conversely, diverse pncA mutations were identified within four genotypic clusters possessing identical IS6110-RFLPs, spoligotypes, and mutations in katG and rpoB, while a fifth cluster with identical katG and pncA sequences (P strain; spoligotype S00086) was resolved by different rpoB mutations. 
DISCUSSION
The prevalence of PZA r has been reported to range from 0.8 to 10% among patients with non-MDR TB and from 10 to 85% among patients with MDR TB worldwide (4, 29, 30) . During the study period, TB caused by PZA r M. tuberculosis in NYC was 50% higher than the national average and 20% higher among patients with MDR TB (31) . Moreover, the MDR TB burden in NYC was 2-fold higher than national estimates. Thus, the high prevalence of MDR TB could be an explanation for the high proportion of PZA r we observed. However, the MDR TB incidence in NYC declined over this period (32) , while the incidence of PZA r TB cases increased, indicating that additional factors were contributing to PZA r in this population. To explain the national increase in PZA r , Kurbatova and colleagues proposed that a higher proportion of foreign-born TB patients may reflect international programmatic variation in TB treatment protocols, leading to increased levels of PZA r TB imported to the United States (31). While we observed high proportions of foreign-born TB patients annually (70 to 80%), we did not find being born outside the United States to be a statistically significant risk factor for PZA r in NYC. In contrast to our findings in NYC, a recent analysis of PZA r TB trends over 2 decades in San Francisco found rates similar to the national average and no significant association between PZA r and MDR TB (33).
Our study found AFB smear positivity, clustering, and death to be independently associated with PZA r . Together, these risk factors suggest that patients infected with PZA r strains were infectious, transmitting, and not responding well to treatment. A history of TB was also independently associated with PZA r , perhaps suggesting that a proportion of patients experienced relapses of drug-resistant TB, though relapse data were not available for this analysis (34, 35) . Given the clinical importance of MDR TB and the high proportion of PZA r among these patients, we sought to determine PZA r risk factors in the MDR TB population. Concurrent resistance to EMB and SLDs was the only PZA r risk factor that maintained statistical significance in the adjusted case-control MDR model. While a strong association between MDR-PZA r and EMB r has been associated with the inappropriate use of standard short-course therapy in patients with MDR TB (36), we do not have sufficient evidence here to address this question. A larger proportion of MDR-PZA r among clustered versus nonclustered strains suggests that primary transmission was responsible for more PZA r than acquired resistance within the MDR TB population.
Based on our molecular examination of MDR strains, we were able to further refine our cluster analysis. In particular, we identified MDR TB clusters with IS6110-RFLP; spoligotype; and katG, rpoB, and pncA mutations identical to those previously described 
